Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .
Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial
Objective To assess the effect of orlistat plus diet compared with diet alone in promoting weight loss and blood pressure reduction in hypertensive , overweight/obese patients . Design A pragmatic r and omized , controlled trial . Setting Hypertension clinic of a university hospital . Patients Hypertensive patients aged 18–75 years with a body mass index greater than 25 kg/m2 . Interventions Orlistat 360 mg/day combined with a hypocaloric diet ( treatment group ) , or a calorie-restricted diet alone ( control group ) . Main outcome measures Primary outcomes were reductions in weight and blood pressure . Secondary outcomes were decreases in lipid and glucose concentrations . A subgroup analysis of the main outcomes among diabetic and non-diabetic patients was also performed . Results A total of 204 patients were included in the intention-to-treat analysis . After 12 weeks the orlistat group lost , on average , 3.7 kg and the control group lost 2.0 kg in weight ( P < 0.001 ) . Systolic ( SBP ) and diastolic ( DBP ) blood pressures decreased by 15.3 and 11.4 mmHg , respectively , in the group given orlistat plus a hypocaloric diet and by 11.6 and 5.2 mmHg , respectively , in the control group given the calorie-restricted diet alone ( P = 0.25 and P = 0.0004 , respectively ) . Fasting glucose ( 0.82 and 0.17 mmol/l , P = 0.01 ) and total cholesterol ( 0.85 and 0.56 mmol/l , P = 0.05 ) were reduced to a greater extent with orlistat than with diet alone . The mean reduction in triglycerides with orlistat plus the hypocaloric diet was 0.75 mmol/l and that in the control group was 0.30 mmol/l ( P = 0.28 ) ; the increases in high-density lipoprotein cholesterol were 0.05 and 0.00 mmol/l , respectively , in the two groups ( P = 0.17 ) . Treatment improved blood pressure and glucose control in the individuals with diabetes , but not in those without diabetes . Conclusion In both groups there was a reduction in weight , blood pressure and metabolic parameters . The orlistat group performed better in reducing weight , DBP , glucose and cholesterol . Results show that even a small reduction in weight helps to control blood pressure and glucose . The cost – benefit of the use of orlistat should be evaluated for hypertensive obese patients
Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .